New drug candidate LEO 158968 put to the test in healthy volunteers
NCT ID NCT05682352
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new compound called LEO 158968 in 120 healthy adults aged 18 to 60. The main goal was to check for side effects and see how well the drug is tolerated, as well as how it moves through and leaves the body. Participants received either the drug or a placebo in increasing doses. This study does not aim to treat any disease, but to gather important safety information for future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
LEO Pharma Investigational Site
Groningen, 9728, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test